The following is a section of the JBRF response to the proposal of the new classification DMDD.  The response was submitted to the American Psychiatric Association in 2010. This reprint has been edited from the original form. At the time, DMDD was still referred to by its original name; Temper Dysregulation Disorder (TDD). References herein have been changed to DMDD. While JBRF research has distanced itself from bipolar disorder, at the time of this writing it was not as clear a separation.



We have serious concerns that both the intended and unintended consequences of the Disruptive Mood Dysregulation Disorder (DMDD) diagnosis will obstruct the identification and appropriate treatment of many children who are affected by a bipolar condition.  For some of them, this could come with life threatening consequences.

Investigators who defined DMDD found a lifetime prevalence of SMD (the precursor to DMDD) of 3.3% in youth 9-19 years of age (Brotman et al., 2006).  Having thus identified the significant presence of a previously un-delineated condition, one which had heretofore been associated with bipolar disorder not-otherwise-specified (BP-NOS), it seems clear that investigators and the Work Group members expect operationalization of the DMDD diagnosis to re-assign a great number of children from a BP-NOS diagnosis to DMDD, a non-bipolar condition, and that the presence of this new diagnosis is likely to decrease the number of BP-NOS diagnoses in the future.

Alternatively, research supported by the JBRF found that two-thirds of children identified from a study of youth at risk for, or who were diagnosed in the community with bipolar disorder (n = 2,795) exhibit some level of the Fear of Harm (FOH) trait (Papolos et al., 2009). This heritable and defining feature of a novel subphenotype of juvenile-onset bipolar disorder is associated with the most severe forms of mania and depression, as well as the highest rates of hospitalization compared to non-FOH subjects. These findings inform us that, despite the alarm over increases in the rates of pediatric bipolar diagnoses, it is likely that approximately two-thirds of these children do indeed belong to a bipolar spectrum.

The above two expectations:

  • that many children who currently receive a BP-NOS diagnosis, or who would have received one in the future, will instead, be diagnosed with DMDD, a non-bipolar classification, and,
  • that approximately two-thirds of the children at risk for or diagnosed with bipolar disorder (BD) are appropriately included in the BD population,

cannot both be true.

If the FOH phenotype is a well-conceived phenotype, and if its prevalence is as substantial as our research shows it to be, then we fear that DSM inclusion of the proposed DMDD classification, with its overlapping symptoms of severe and chronic irritability marked by disproportionate frustration, will cause a large number of children to be erroneously assigned to a DMDD diagnosis when in fact, they struggle with a bipolar condition.

We believe that this will be the case.  As explained elsewhere, we have serious concerns with both the concepts and methodology used to arrive at the DMDD classification and we suspect it to be a cleaved-off fragment of the FOH condition.

However, even if we were to disregard our criticisms and accept the DMDD classification and prevalence at face value, its operationalization would still leave children in the BP-NOS classification and we are likewise concerned that the same misdiagnosis will occur but only with a relatively smaller number of children.

It could be argued that both of these concerns are unwarranted; that the exclusionary criteria of DMDD would prevent children with FOH from receiving a DMDD diagnosis.

Since symptoms of FOH include (Papolos et al., 2009) :

Has elated or silly, goofy, giddy mood states,

Has exaggerated ideas about self or abilities, and

Tells tall tales; embellishes or exaggerates,

and Criterion H of the DMDD Draft Criteria (APA DSM5 Development, 2010a) states:

In the past year, there has never been a distinct period lasting more than one day during which abnormally elevated or expansive mood was present most of the day for most days, and the abnormally elevated or expansive mood was accompanied by the onset, or worsening, of three of the “B” criteria of mania,

then technically, children who fit the FOH phenotype would be excluded from a DMDD diagnosis and would continue to be diagnosed under the BP-NOS classification.

However, due to practical clinical realities, we believe that this important differentiation is not what will happen.  The combined effects of the following considerations will strongly bias towards a DMDD classification:

  • DMDD is introduced as a correction to a highly controversial and confusing illness.  Professionals have faced a diagnostic conundrum when asked to assign a bipolar diagnosis to a presentation which is often so dissimilar from defined criteria of adult BD I or II.  Families are exhausted and desperate for an explanation as to why their children are not finding effective relief under the current assumptions and treatment options.  The absence of any further articulation of a developmental aspect of bipolar disorder makes migration to this classification a default logical next action.
  • The fact that the DMDD classification brings with it a less-imposing lifetime prognosis and the potential for lower stigma makes DMDD a comparatively desirable diagnosis to BD.  While these issues should have nothing to do with assessing a child’s condition, in a real world devoid of biological markers, they assert tremendous pressure.
  • The severe chronic irritability punctuated with rage which defines the DMDD phenotype presents with highly observable, recognizable and problematic behavior.  It undermines, and comes crashing into, the child’s and family’s life with much notice. On the other hand, hypomania, which would exclude a child from a DMDD diagnosis, is much more difficult to discern and rarely prompts clinical attention as it is often perceived as normal well-being (Angst, 2003, 2007).

Identification of hypomania in children is even more challenging than its identification in adults given its overlap with developmental behaviors.   It is well established that “there is a generally low parent-child agreement in reporting symptoms of mania” (Stringaris et al., in review).  Parents may not be as tuned in to pick up changes from baseline, the differences that would distinguish the behavior from developmental norms, or they may even regard the changed energy state as a relief from the irritable mood (Youngstrom et al., 2008).  All of these diminish the likelihood of the hypomania receiving notice.

Further, the increasing recognition of BD Spectrum Disorder (Ghaemi et al, 2002) and the importance of subsyndromal symptoms bring BD more into line with the often subsyndromal, or non-classic, presentation of BD in children (Danner et al., 2009).  Judd et al. (2003) found that BD II adults spent less than 1% of their total time in syndrome-level hypomania.  Given this frequency for an adult who meets DSM criteria, how likely can we expect the presentation of DSM hypomania to be present in a child with BP-NOS?

When the presence of (hypo)mania is the only thing that sends the diagnosis back in to a bipolar realm, then there will undoubtedly be many cases in which the wrong call is made.  We would suggest that this call could be made more assuredly if the presence of additional important features associated with (hypo)mania were also determined.  However the DMDD criteria do not provide any.

  • The above criticism notwithstanding, an ideal clinical setting should be able to detect the presence of hypomania.  A capable clinician using thorough diagnostic practices, given sufficient clinical opportunity, and reliable input from a person who is able to observe the child’s behavior and symptoms outside of the clinical setting, should be able to pick up the mood symptoms of hypomania and identify the simultaneous change from baseline in order to make the “right call” between DMDD and BP-NOS.  But rarely is this ideal possible.


  • Case loads in some of the most vulnerable population centers; schools, youth correctional facilities, and under-supported communities, are simply not able to provide the type of individual, well considered attention that would allow for such observation and analysis.  In these cases we cannot help but think that the more obvious and circumstantially problematic behaviors will dictate the diagnosis.
  • Even in clinical settings in which the time and the attention of the clinician are not so constrained, there is a bias against careful differentiation.  In her article Dictionary of Disorder, (Spiegel, 2005) Alix Spiegel writes,

Reliability is probably lowest in the place where the most diagnoses are made: the therapist’s office.  As Tom Widiger, who served as head of research for the DSM-IV, points out, “There are lots of studies which show that clinicians diagnose most of their patients with one particular disorder and really don’t systematically assess for other disorders.  They have a bias in reference to the disorder that they are especially interested in treating and believe that most of their patients have.

A fresh unbiased examination of all the inclusionary and exclusionary criteria simply gives way to practical experience.  Given all the above comments that push a DMDD diagnosis into the foreground, it is reasonable to be concerned that many clinicians will come to apply the DMDD diagnosis more often than would be justified.

  • By not simultaneously announcing a proposal which would provide greater guidance and clarity for non-classic BD, a need which is now greater than ever given the potential for confusion with DMDD, professionals and the public alike cannot help but interpret that the Work Groups do not confer upon it equal importance to operationalization of DMDD.  The vast media coverage of the DMDD proposal announcement, including a feature story on NPR’s All Things Considered and supportive comments by Dr. Alan Schatzberg, APA President in the March 5, 2010 Psychiatric News, has already affected clinical decisions and research grant requirements.

We fear that the above mentioned concerns will strongly bias the diagnosis of many mood impaired children towards DMDD.  For those children who do have a bipolar condition, the effects of misdiagnosis could be tragic.  The following excerpt from the Justification for DMDD (APA DSM5, 2010b) makes quite clear how divergent the treatment protocol would be for a child who receives one diagnosis or the other.

The question of whether youth with the DMDD phenotype have a form of BD, vs. a syndrome on a pathophysiological continuum with anxiety disorders, unipolar depression, and ADHD, has profound treatment implications. That is, if DMDD is a form of BD, first-line treatment would consist of atypical antipsychotic medication and/or mood stabilizers. On the other hand, if DMDD is on a continuum with unipolar depressive disorders, anxiety disorders, and ADHD, first-line treatment would consist of serotonergic reuptake inhibitor antidepressants (SSRI’s) and stimulants. Importantly, the latter two medication classes are considered relatively contraindicated in BD. Thus, nosological questions regarding DMDD have significant treatment implications, and it is essential that clinical trials to address this question be launched. (italics ours)

While this may be re-assuring for those who have confidence in the DMDD classification and the clinical capability to differentiate it from BP-NOS, it causes great worry for us.  Treatment with SSRI’s and stimulants without prior mood stabilization could be catastrophic if a bipolar condition really exists and is not diagnosed (Ghaemi et al., 2003).  As Faedda et al. (2004) point out:

Of 82 juvenile BD patients, 57 (69%) had been given a mood-elevating agent at least once; 33/57 (58%) so-exposed met criteria for [treatment induced episodic mania] TEM, with median latency of 14 days; TEM was observed twice as often with antidepressants as stimulants (44% vs. 18%). TEM led to first-recognition of BPD in 14 cases (17%), and some drug-exposed children (4-9%) had prominent suicidal, homicidal or psychotic behavior. In addition to recent exposure to a mood-elevating agent, TEM was associated with early-onset anxiety and female gender.

Given the “significant treatment implications”, we reiterate our request for field trials that would clarify the specific clinical and physiological characteristics of children with DMDD in comparison to those with FOH.


  1. Pingback: pickleball
  2. Pingback: hotels burlington
  3. Pingback: water slide
  4. Pingback: interserver coupon
  5. Pingback: how to
  6. Pingback: read more
  7. Pingback: my company
  8. Pingback: a fantastic read
  9. Pingback: original site
  10. Pingback: look at this site
  11. Pingback: additional hints
  12. Pingback: More Bonuses
  13. Pingback: Continued
  14. Pingback: Discover More
  15. Pingback: see post
  16. Pingback: look here
  17. Pingback: read more
  18. Pingback: best info
  19. Pingback: new website
  20. Pingback: news
  21. Pingback: how to
  22. Pingback: about
  23. Pingback: useful reference
  24. Pingback: imp source
  25. Pingback: a fantastic read
  26. Pingback: my response
  27. Pingback: their explanation
  28. Pingback: Visit Website
  29. Pingback: her latest blog
  30. Pingback: More Bonuses
  31. Pingback: you could try here
  32. Pingback: Learn More
  33. Pingback: Get the facts
  34. Pingback: official statement
  35. Pingback: important source
  36. Pingback: click here
  37. Pingback: click here
  38. Pingback: click here
  39. Pingback: click here
  40. Pingback: read more
  41. Pingback: read more
  42. Pingback: read more
  43. Pingback: read more
  44. Pingback: website
  45. Pingback: click here
  46. Pingback: read more
  47. Pingback: official site
  48. Pingback: her latest blog
  49. Pingback: Clicking Here
  50. Pingback: best value
  51. Pingback: new source
  52. Pingback: best news
  53. Pingback: learn now
  54. Pingback: click here
  55. Pingback: read more
  56. Pingback: important
  57. Pingback: find
  58. Pingback: figure out
  59. Pingback: continue reading
  60. Pingback: what to do
  61. Pingback: where to look
  62. Pingback: insight
  63. Pingback: quality article
  64. Pingback: Sperry's for women
  65. Pingback: useful reference
  66. Pingback: their explanation
  67. Pingback: Homepage
  68. Pingback: a fantastic read
  69. Pingback: find this
  70. Pingback: browse this site
  71. Pingback: my response
  72. Pingback: More hints
  73. Pingback: Get the facts
  74. Pingback: official statement
  75. Pingback: try this web-site
  76. Pingback: explanation
  77. Pingback: mitogenic
  78. Pingback: sperrys uk womens
  79. Pingback: read more
  80. Pingback: check my blog
  81. Pingback: click site
  82. Pingback: my review here
  83. Pingback: useful reference
  84. Pingback: Get More Info
  85. Pingback: see here
  86. Pingback: this website
  87. Pingback: great post to read
  88. Pingback: my company
  89. Pingback: imp source
  90. Pingback: click to read more
  91. Pingback: see it here
  92. Pingback: Homepage
  93. Pingback: find this
  94. Pingback: Bonuses
  95. Pingback: read this article
  96. Pingback: click here now
  97. Pingback: browse this site
  98. Pingback: check here
  99. Pingback: original site
  100. Pingback: my response
  101. Pingback: this page
  102. Pingback: click here
  103. Pingback: click here
  104. Pingback: click here
  105. Pingback: read more
  106. Pingback: read more
  107. Pingback: read more
  108. Pingback: what is new
  109. Pingback: what is new
  110. Pingback: what is new
  111. Pingback: what is new
  112. Pingback: aloe vera
  113. Pingback: aloe vera for acne
  114. Pingback: acne skin
  115. Pingback: more info
  116. Pingback: click here
  117. Pingback: read article
  118. Pingback: website
  119. Pingback: source
  120. Pingback: important
  121. Pingback: news
  122. Pingback: url
  123. Pingback: niagen pills
  124. Pingback: read more
  125. Pingback: click here
  126. Pingback: news
  127. Pingback: important
  128. Pingback: new article
  129. Pingback: best information
  130. Pingback: exceptional
  131. Pingback: see this here
  132. Pingback: Visit Website
  133. Pingback: keep reading
  134. Pingback: home page
  135. Pingback: more about this
  136. Pingback: hosting24 coupon
  137. Pingback: More Bonuses
  138. Pingback: click resources
  139. Pingback: Get the facts
  140. Pingback: official statement
  141. Pingback: click reference
  142. Pingback: you can look here
  143. Pingback: her explanation
  144. Pingback: why not try here
  145. Pingback: informative post
  146. Pingback: click here
  147. Pingback: read more
  148. Pingback: info
  149. Pingback: website
  150. Pingback: news
  151. Pingback: link
  152. Pingback: best source
  153. Pingback: post
  154. Pingback: next
  155. Pingback: click reference
  156. Pingback: visit site
  157. Pingback: look here
  158. Pingback: Going Here
  159. Pingback: click to read
  160. Pingback: a knockout post
  161. Pingback: look at here now
  162. Pingback: important link
  163. Pingback: Extra resources
  164. Pingback: probiotics america
  165. Pingback: Niagen review
  166. Pingback: click here
  167. Pingback: read more
  168. Pingback: visit them
  169. Pingback: new source
  170. Pingback: important
  171. Pingback: information
  172. Pingback: read more
  173. Pingback: information
  174. Pingback: website
  175. Pingback: news
  176. Pingback: best source
  177. Pingback: best source
  178. Pingback: click here
  179. Pingback: Source
  180. Pingback: have a peek here
  181. Pingback: Check This Out
  182. Pingback: this contact form
  183. Pingback: navigate here
  184. Pingback: weblink
  185. Pingback: check over here
  186. Pingback: this content
  187. Pingback: click here
  188. Pingback: have a peek here
  189. Pingback: Check This Out
  190. Pingback: this contact form
  191. Pingback: navigate here
  192. Pingback: check over here
  193. Pingback: this content
  194. Pingback: check my blog
  195. Pingback: his explanation
  196. Pingback: more info here
  197. Pingback: official site
  198. Pingback: look at this site
  199. Pingback: visit
  200. Pingback: check it out
  201. Pingback: see this
  202. Pingback: see this here
  203. Pingback: see this here
  204. Pingback: feres
  205. Pingback: feres inşaat
  206. Pingback: feres gayrimenkul
  207. Pingback: feres
  208. Pingback: additional hints
  209. Pingback: Bonuses
  210. Pingback: a fantastic read
  211. Pingback: find more info
  212. Pingback: find more info
  213. Pingback: great post to read
  214. Pingback: my company
  215. Pingback: my review here
  216. Pingback: click site
  217. Pingback: check my blog
  218. Pingback: this content
  219. Pingback: click here
  220. Pingback: midogen review
  221. Pingback: midogen
  222. Pingback: midogen review
  223. Pingback: midogen
  224. Pingback: niagen reviews
  225. Pingback: read more
  226. Pingback: niagen review
  227. Pingback: niagen
  228. Pingback: More Bonuses
  229. Pingback: Check This Out
  230. Pingback: navigate here
  231. Pingback: additional reading
  232. Pingback: great post to read
  233. Pingback: more information
  234. Pingback: go now
  235. Pingback: Related Site
  236. Pingback: useful link
  237. Pingback: useful link
  238. Pingback: pop over here
  239. Pingback: read more
  240. Pingback: click here
  241. Pingback: pop over here
  242. Pingback: Full Article
  243. Pingback: read more
  244. Pingback: pop over here
  245. Pingback: Full Article
  246. Pingback: read more
  247. Pingback: read more
  248. Pingback: click here
  249. Pingback: pop over here
  250. Pingback: Full Article
  251. Pingback: read more
  252. Pingback: click here
  253. Pingback: pop over here
  254. Pingback: Full Article
  255. Pingback: Full Article
  256. Pingback: read more
  257. Pingback: click here
  258. Pingback: check over here
  259. Pingback: click site
  260. Pingback: news
  261. Pingback: this content
  262. Pingback: click here
  263. Pingback: check my blog
  264. Pingback: my company
  265. Pingback: imp source
  266. Pingback: this page
  267. Pingback: Get More Info
  268. Pingback: Homepage
  269. Pingback: great post to read
  270. Pingback: useful reference
  271. Pingback: my review here
  272. Pingback: a fantastic read
  273. Pingback: official site
  274. Pingback: directory
  275. Pingback: his explanation
  276. Pingback: browse this site
  277. Pingback: dig this
  278. Pingback: read this article
  279. Pingback: original site
  280. Pingback: Bonuses
  281. Pingback: look at this site
  282. Pingback: More hints
  283. Pingback: page
  284. Pingback: her latest blog
  285. Pingback: additional hints
  286. Pingback: More Bonuses
  287. Pingback: check over here
  288. Pingback: this content
  289. Pingback: weblink
  290. Pingback: navigate here
  291. Pingback: navigate here
  292. Pingback: this contact form
  293. Pingback: have a peek here
  294. Pingback: rialudi
  295. Pingback: check my blog
  296. Pingback: great post to read
  297. Pingback: see here

Comments are closed.